Skip to main content
Top
Published in: International Urology and Nephrology 2/2014

01-02-2014 | Urology - Original Paper

Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies?

Authors: G. Gopal Rao, Deepak Batura

Published in: International Urology and Nephrology | Issue 2/2014

Login to get access

Abstract

Purpose

To report the incidence of emergency admissions attributable to infective complications of transrectal ultrasound-guided prostate biopsy (TGB) and evaluate appropriateness of antimicrobial prophylaxis.

Methods

Retrospective cross-sectional study of patients undergoing TGB at the North West London Hospitals in 2009–2011. Demographic information of patients who had emergency admission within 30 days of TGB, length of hospital stay and microbiology results were obtained from the hospital’s information system, medical records and laboratory information system. All patients received ciprofloxacin and amikacin prophylaxis.

Results

1,419 TGB were performed in 1,276 patients. Forty-eight (3.3 %) patients had emergency admissions. Thirty-three (2.3 %) admissions were due to complications from TGB, while 15 (1 %) were for unrelated reasons. 30/33 (90 %, overall 2.1 %) of admissions from TGB complications were due to confirmed infections or systemic inflammatory response syndrome (SIRS). The rest were admitted with urinary retention. Admission rates due to TGB complications and infection/SIRS remained consistent over the 3 years (2009: TGB complications—2 %, TGB infection/SIRS—1.8 %; 2010: TGB complications—2.4 %, TGB infections/SIRS—2.2 %; 2011: TGB complications—2.6 %, TGB infection/SIRS—2.4 %; P > 0.05). All 11 cases with bacteraemia were caused by ciprofloxacin-resistant but amikacin-susceptible E. coli.

Conclusions

We observed a consistent rate of emergency admissions for complications following TGB; 90 % of these were due to infections. Ciprofloxacin-resistant but amikacin-sensitive E. coli was isolated in all bacteriologically confirmed infections. These results suggest that infective complications of TGB cannot be altogether eliminated despite appropriate antimicrobial prophylaxis. Therefore, additional strategies for reduction in biopsy-related admissions due to infections have to be considered.
Literature
1.
go back to reference Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183:963–968PubMedCrossRef Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183:963–968PubMedCrossRef
2.
go back to reference Zlotta AR, Nam RK (2012) To biopsy or not to biopsy—thou shall think twice. Eur Urol 61:1115–1117PubMedCrossRef Zlotta AR, Nam RK (2012) To biopsy or not to biopsy—thou shall think twice. Eur Urol 61:1115–1117PubMedCrossRef
3.
go back to reference Loeb S, van Den HS, Zhu X, Bangma CH, Schroder FH, Roobol MJ (2012) Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 61:1110–1114PubMedCrossRef Loeb S, van Den HS, Zhu X, Bangma CH, Schroder FH, Roobol MJ (2012) Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 61:1110–1114PubMedCrossRef
4.
go back to reference Wagenlehner FM, Van OE, Tenke P, Tandogdu Z, Cek M, Grabe M, Wullt B, Pickard R, Naber KG, Pilatz A, Weidner W, Bjerklund-Johansen TE (2012) Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 63:521–527PubMedCrossRef Wagenlehner FM, Van OE, Tenke P, Tandogdu Z, Cek M, Grabe M, Wullt B, Pickard R, Naber KG, Pilatz A, Weidner W, Bjerklund-Johansen TE (2012) Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 63:521–527PubMedCrossRef
5.
go back to reference Batura D, Gopal Rao G (2013) The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother 68:247–249PubMedCrossRef Batura D, Gopal Rao G (2013) The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother 68:247–249PubMedCrossRef
6.
go back to reference Patel U, Dasgupta P, Amoroso P, Challacombe B, Pilcher J, Kirby R (2012) Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int 109:1781–1785PubMedCrossRef Patel U, Dasgupta P, Amoroso P, Challacombe B, Pilcher J, Kirby R (2012) Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int 109:1781–1785PubMedCrossRef
7.
go back to reference Ganeswaran D, Sweeney C, Yousif F, Lang S, Goodman C, Nabi G (2012) Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer. World J Urol (Epub ahead of print). doi:10.1007/s00345-012-0893-2 Ganeswaran D, Sweeney C, Yousif F, Lang S, Goodman C, Nabi G (2012) Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer. World J Urol (Epub ahead of print). doi:10.​1007/​s00345-012-0893-2
8.
go back to reference Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, Johnson AP, George RC (2002) Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990–1999. Emerg Infect Dis 8:473–478PubMedCrossRef Livermore DM, James D, Reacher M, Graham C, Nichols T, Stephens P, Johnson AP, George RC (2002) Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990–1999. Emerg Infect Dis 8:473–478PubMedCrossRef
9.
go back to reference Batura D, Gopal Rao G, Nielsen PB (2010) Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 106:1017–1020PubMedCrossRef Batura D, Gopal Rao G, Nielsen PB (2010) Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 106:1017–1020PubMedCrossRef
10.
go back to reference Andrews JM (2009) BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 64:454–489PubMedCrossRef Andrews JM (2009) BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 64:454–489PubMedCrossRef
11.
go back to reference Livermore DM, Hawkey PM (2005) CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 56:451–454PubMedCrossRef Livermore DM, Hawkey PM (2005) CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 56:451–454PubMedCrossRef
12.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald W (2009) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 136(5 Suppl):e28 Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald W (2009) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 136(5 Suppl):e28
13.
go back to reference Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186:1830–1834PubMedCrossRef Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186:1830–1834PubMedCrossRef
14.
go back to reference Sanders A, Buchan N (2013) Infection-related hospital admissions after transrectal biopsy of the prostate. ANZ J Surg 83:246–248PubMedCrossRef Sanders A, Buchan N (2013) Infection-related hospital admissions after transrectal biopsy of the prostate. ANZ J Surg 83:246–248PubMedCrossRef
15.
go back to reference Rajgopal R, Wang Y, Faber KJ, Izawa JI (2012) Vertebral osteomyelitis following transrectal ultrasound-guided biopsy of the prostate. Can Urol Assoc J 6:E20–E22PubMedCentralPubMed Rajgopal R, Wang Y, Faber KJ, Izawa JI (2012) Vertebral osteomyelitis following transrectal ultrasound-guided biopsy of the prostate. Can Urol Assoc J 6:E20–E22PubMedCentralPubMed
16.
go back to reference Williamson DA, Roberts SA, Paterson DL, Sidjabat H, Silvey A, Masters J, Rice M, Freeman JT (2012) Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 54:1406–1412PubMedCrossRef Williamson DA, Roberts SA, Paterson DL, Sidjabat H, Silvey A, Masters J, Rice M, Freeman JT (2012) Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 54:1406–1412PubMedCrossRef
17.
go back to reference Rogers BR, Batura D, Gopal Rao G (2013) Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: our experience in North West London. Clin Infect Dis 56:465–466PubMedCrossRef Rogers BR, Batura D, Gopal Rao G (2013) Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: our experience in North West London. Clin Infect Dis 56:465–466PubMedCrossRef
18.
go back to reference Hernandez-Graulau JM (2009) Editorial comment. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 74:338–339PubMedCrossRef Hernandez-Graulau JM (2009) Editorial comment. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 74:338–339PubMedCrossRef
19.
go back to reference Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J (2012) Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy–should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 18:575–581PubMedCrossRef Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J (2012) Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy–should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 18:575–581PubMedCrossRef
20.
go back to reference Liss MA, Peeples AN, Peterson EM (2011) Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol 49:1116–1118PubMedCentralPubMedCrossRef Liss MA, Peeples AN, Peterson EM (2011) Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol 49:1116–1118PubMedCentralPubMedCrossRef
21.
go back to reference Batura D, Gopal Rao G, Nielsen PB, Charlett A (2011) Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int 107:760–764PubMedCrossRef Batura D, Gopal Rao G, Nielsen PB, Charlett A (2011) Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int 107:760–764PubMedCrossRef
22.
go back to reference Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, Lotan Y (2013) Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol 189:535–540PubMedCrossRef Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, Lotan Y (2013) Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol 189:535–540PubMedCrossRef
23.
go back to reference Ho HS, Ng LG, Tan YH, Yeo M, Cheng CW (2009) Intramuscular gentamicin improves the efficacy of ciprofloxacin as an antibiotic prophylaxis for transrectal prostate biopsy. Ann Acad Med Singap 38:212–216PubMed Ho HS, Ng LG, Tan YH, Yeo M, Cheng CW (2009) Intramuscular gentamicin improves the efficacy of ciprofloxacin as an antibiotic prophylaxis for transrectal prostate biopsy. Ann Acad Med Singap 38:212–216PubMed
24.
go back to reference Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, Hayami H (1998) Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol 5:243–246PubMedCrossRef Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, Hayami H (1998) Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol 5:243–246PubMedCrossRef
25.
go back to reference Briffau R, Coloby P, Bruyere F, Ouaki F, Pires C, Dore B, Irani J (2009) One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy. BJU Int 103:1069–1073CrossRef Briffau R, Coloby P, Bruyere F, Ouaki F, Pires C, Dore B, Irani J (2009) One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy. BJU Int 103:1069–1073CrossRef
26.
go back to reference Hori S, Sengupta A, Joannides A, Balogun-Ojuri B, Tilley R, McLoughlin J (2010) Changing antibiotic prophylaxis for transrectal ultrasound-guided prostate biopsies: are we putting our patients at risk? BJU Int 106:1298–1302PubMedCrossRef Hori S, Sengupta A, Joannides A, Balogun-Ojuri B, Tilley R, McLoughlin J (2010) Changing antibiotic prophylaxis for transrectal ultrasound-guided prostate biopsies: are we putting our patients at risk? BJU Int 106:1298–1302PubMedCrossRef
27.
go back to reference Bradley LA, Palomaki GE, Gutman S Samson D, Aronson N (2013) Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol (Epub ahead of print). doi:10.1016/j.juro.2013.02.005 Bradley LA, Palomaki GE, Gutman S Samson D, Aronson N (2013) Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol (Epub ahead of print). doi:10.​1016/​j.​juro.​2013.​02.​005
28.
go back to reference Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ (2013) Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. J Urol 189:1697–1701PubMedCentralPubMedCrossRef Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ (2013) Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. J Urol 189:1697–1701PubMedCentralPubMedCrossRef
29.
go back to reference Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, Malavaud B (2012) Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 62:986–996PubMedCrossRef Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, Malavaud B (2012) Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 62:986–996PubMedCrossRef
30.
go back to reference Kirby R, Fitzpatrick JM (2012) Optimising repeat prostate biopsy decisions and procedures. BJU Int 109:1750–1754PubMedCrossRef Kirby R, Fitzpatrick JM (2012) Optimising repeat prostate biopsy decisions and procedures. BJU Int 109:1750–1754PubMedCrossRef
31.
go back to reference Lorber G, Duvdevani M, Friedman M, Lavy E, Landau EH, Gofrit ON, Pode D, Steinberg D (2013) Sustained-release antibacterial varnish-coated biopsy needle for reduction of infection rates following prostate biopsy-in vitro model. J Endourol 27:277–283PubMedCrossRef Lorber G, Duvdevani M, Friedman M, Lavy E, Landau EH, Gofrit ON, Pode D, Steinberg D (2013) Sustained-release antibacterial varnish-coated biopsy needle for reduction of infection rates following prostate biopsy-in vitro model. J Endourol 27:277–283PubMedCrossRef
Metadata
Title
Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies?
Authors
G. Gopal Rao
Deepak Batura
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-013-0529-5

Other articles of this Issue 2/2014

International Urology and Nephrology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.